莫雷西嗪治疗阵发性心房颤动110例

Moricizine for Treating Paroxysmal Atrial Fibrillation in 110 cases

目的探讨莫雷西嗪治疗阵发性房颤患者的临床疗效及安全性。方法选择2012年4月至2014年7月医院收治的阵发性房颤患者110例,随机分为对照组和观察组,各55例。两组患者治疗前3 d停用抗心律失常药物,对照组在治疗原发病基础上给予口服胺碘酮片治疗,观察组在对照组治疗基础上口服莫雷西嗪。结果观察组阵发性房颤的改善总有效率为96.36%,显著高于对照组的85.45%(P<0.05)。治疗后,两组患者心率、24 h房颤发作次数、24 h房颤发作时间较治疗前大幅度降低(P<0.05),观察组较对照组明显降低(P<0.05)。治疗后,两组患者Pmax以及Pd与治疗前相比显著改善(P<0.05),观察组改善幅度明显优于对照组(P<0.05)。两组不良反应均较轻,无统计学意义(P>0.05)。结论莫雷西嗪治疗阵发性房颤临床疗效显著,可有效改善患者阵发性房颤的发作情况,且无明显不良反应发生,值得临床推广。

Objective To investigate the clinical efficacy of moricizine for treating Paroxysmal atrial fibrillation and its safety. Methods 100 cases of Paroxysmal atrial fibrillation from APril 2012 to July 2014 in the hosPital were selected and randomly divided into the control grouP and the observation grouP, 55 cases in each grouP. The two grouPs stoPPed taking anti-arrhythmic drugs 3 d before treatment;the control grouP received amiodarone theraPy orally on the basis of the Primary disease treatment, and the observation grouP received moracizine orally on the basis of the control grouP. Results The total effective rate of atrial fibrillation imProvement of the observation grouP was 96. 36%, which was significantly better than 85. 45% of the control grouP （ P 〈 0. 05 ） . After treatment, the heart rate, 24 h atrial fibrillation frequency, 24 h atrial fibrillation of the two grouPs were significantly reduced comPared with before treatment （ P 〈 0. 05 ） , and the reduction in the observation grouP was better than those in the control grouP （ P 〈 0. 05 ） . After treatment, the Pmax and Pd of the two grouPs were significantly imProved comPared with before treatment （ P 〈 0. 05 ） , and the imProvement of the observation grouP was more than those of the control grouP （ P 〈 0. 05 ） . The adverse reactions of the two grouPs were both mild, with no statistically significant difference （ P 〉 0. 05 ） . Conclusion Moricizine in treating Paroxysmal atrial fibrillation has significant clinical effect, can effectively imProve the situation of Paroxysmal atrial fibrillation, has no significant adverse reactions, and is worth of clinical aPPlication.